Finzati - Logo
DVAX logo

Dynavax Technologies Corporation

DVAX • Drug Manufacturers - Specialty & Generic
$0.00
— 0.00 (0.00%)
EarningsLatest report: Sep 30, 2025
BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.
Market Cap
$1.82B
Growth
—
Cash Flow
4/5
Trend
Mostly stable
Evidence
Positive revenue growth · 46.6%Positive free cash flow · 0.46Consistent free cash flow · 4/5Manageable debt level · 0.43Healthy liquidity · 10.8
Financial data as of: Sep 30, 2025, 12:00 AM UTCLast earnings update: Nov 5, 2025, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$0.00
Change0.00%
Market Cap$1.82B
52W Range9.20 - 15.73
Beta0.93
Gross Margin82.17%
Oper. Margin-1.49%
Profit Margin9.85%
Debt/Eq0.43
Current Ratio10.80
Quick Ratio9.91
Target$27.00

Investment DNA

How strong this company looks for long-term investors

60
out of 100
Business Quality
Margins, moat, returns
56/100
Financial Strength
Debt, cash, stability
75/100
Growth Potential
Revenue and expansion
58/100
Price Attractiveness
Cheap or expensive today
46/100
Why this score▼
Positive revenue growth · 46.6%Positive free cash flow · 0.46Consistent free cash flow · 4/5Manageable debt level · 0.43Healthy liquidity · 10.8Expensive earnings multiple · 60.81

Analyst view

Analyst sentiment and price target

Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-06-06
Low
$20.00
Mean
$27.00
Median
$29.00
High
$32.00

Company Overview

IPO: 2/19/2004
Industry: Drug Manufacturers - Specialty & Generic
P/B i: 2.78
Debt / Equity i: 0.43
Operating Margin: -1.49%
Net Margin: 9.85%
ROE i: -
ROIC: -

Financial Health

Score15 / 20
Debt / Equity: 0.43
Current Ratio: 10.80
Quick Ratio: 9.91
Status: Good

Insider Transactions

Recent executive and insider activity

⚠ 2 high-volume insider sells detected
Deep Track Biotechnology Master Fund, Ltd.
Transaction: 02/10/2026
SELL
Change
-15,726,349
Price
$0.00
Filing
02/11/2026
Type
SELL
Novack David F
Transaction: 02/10/2026
SELL
Change
-37,576
Price
Not reported
Filing
02/10/2026
Type
SELL
Novack David F
Transaction: 02/10/2026
SELL
Change
-63,334
Price
Not reported
Filing
02/10/2026
Type
SELL